Chinese Hepatolgy ›› 2026, Vol. 31 ›› Issue (1): 44-48.

• Hepatitis • Previous Articles     Next Articles

A real-world study of Danorevir/Ritonavir combined with Ravidavir in the treatment of HIV with chronic hepatitis C

WU Gui-fang1, WEI Zhen-hua2, YAN Ya-jun1, YANG Wei3, WAN Zhu-qing4, XU Lu5, WANG Yao-fen6, YU Wen-jun7, GONG Xiao-ming8, FENG Ling1, YANG Rong-rong1, JIANG Hong-lin9, LIANG Ke1, GAO Shi-cheng1, KE Heng-ning1   

  1. 1. Zhongnan Hospital of Wuhan University,Wuhan 730071, China;
    2. Hubei Province Suizhou City Junchuan Town Health Center, Suizhou 441322, China;
    3. Suixian Center for Disease Control and Prevention, Suizhou 441309, China;
    4. Yunmeng County People′s Hospital, Xiaogan 432599, China;
    5. Yunmeng Center for Disease Control and Prevention, Xiaogan 432599, China;
    6. The Second Affiliated Hospital of Hubei University of Science and Technology, Xianning 437100, China;
    7. Wuhan First Hospital, Wuhan 430312, China;
    8. Xianning Central Hospital,Xianning 437100, China;
    9. Hubei Provincial Center for Disease Control and Prevention,Wuhan 730079, China
  • Received:2025-01-04 Online:2026-01-31 Published:2026-03-30

PDF (PC)

3

Abstract: Objective To evaluate the efficacy and safety of Danorevir/Ritonavir combined with ravidavir in the treatment of HCV infection and HIV with HCV infection. Methods A prospective, multicenter study of HCV infection and HIV/HCV co-infected persons in a region of Hubei, China, from July 2023 to March 2024. HCV viral load, liver function, and renal function were measured at baseline, at the 4th week of treatment, at the end of treatment, and at the 12 week follow-up. The adverse reactions and laboratory test indexes were observed during the treatment. t test, Friedman test and χ2 test were used for statistical analysis. Univariate and multivariate logistic regression were used to analyze the influencing factors of sustained virological response (SVR). Results A total of 87 patients were enrolled in the study, 66 of whom completed follow-up. There were 15 patients with HCV infection and 51 patients with HCV/HIV co-infection. The rate of SVR in HCV-infected patients was 73.33%, and that in HCV/HIV co-infected individuals was 74.50%, with no significant difference (P=1.000). Multivariate logistic regression analysis showed that the genotype of hepatitis C (OR=4.589,95%CI: 1.272~16.558, P=0.020) was an independent influencing factor for SVR. Adverse events occurred in 34 (51.52%) of 68 patients, including 27 (52.94%) in the HIV/HCV group and 7 (46.67%) in the HCV group, all of which disappeared after symptomatic supportive treatment. Conclusion Danorevir/Ritonavir combined with Ravidavir has a suboptimal antiviral efficacy in the treatment of HCV. HCV genotype 2a is an independent influencing factor for SVR. For patients with genotype 2a, other treatment regimens may need to be selected to increase the SVR rate.

Key words: Hepatitis C virus, AIDS, Co-infection, Direct antiviral drugs, Security